Our results suggest that the PyMT oncogene cannot transdifferentiate β cells or any insulin-producing precursor to an exocrine phenotype or cause progressive neoplasia, regardless of the stage of development at which the oncogene is expressed. The gene discussed is INS; the disease is neoplasm.